As surely as the seasons change and the tides rise, pharma will continue raising the prices of medications wherever and whenever it can.
In one example from last week, the non-profit Institute for Clinical and Economic Review (ICER) found that the new class of cholesterol medications, the PCSK-9s, is grossly overpriced. The first two brands in that class, Repatha from Amgen and Praluent from Sanofi and Regeneron, each go for wholesale prices of more than $14,000 per patient per year. ICER’s analysis concluded that a price representing the true value of those products would fall somewhere between $3,615 and $4,811 a year, a 67 percent discount below their current prices.
Hey, check out all the research scientist jobs. Post your resume today!
